Comment on CMS-2026-1256-0002
Amgen, Inc.SupportBusiness
Summary: Amgen, a pharmaceutical company, supports the CMS proposal to continue New Technology Add-on Payment (NTAP) status for its drug IMDELLTRA for fiscal year 2027. The company argues that the drug remains "new" under current Medicare policy and that continued NTAP status is necessary to ensure patient access to this treatment for small cell lung cancer.
See attached comments.